EyePoint Pharmaceuticals (EYPT) Reports In-Line Q2 EPS

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q2 EPS of ($0.52), in-line with the analyst estimate of ($0.52). Revenue for the quarter came in at $11.3 million versus the consensus estimate of $10.89 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• Paychex beats fourth quarter EPS estimates, stock slides
• Ecolab pops as Citi sees improving setup into Q2 earnings